Visus Therapeutics, Inc.’s Post

Arwen Podesta, MD, ABPN, FASAM, ABIHM, highlights key factors for successful implementation of the use prescription digital therapeutics (PDTs) in clinical settings, discussing how patient care and outcomes are impacted. Watch the K-Cast series to learn more: [link] #ManagedCare #MentalHealthCare #PDT

For anyone who has vendor management/evaluation in their remit, this webinar is "must see viewing". Great topic + Great Panel = Thought provoking ideas

Look at this panel discussion webinar coming up. With experts from the likes of 4c LifeSciences, Kyowa Kirin, ADC Therapeutics, Dragonfly Therapeutics (and of course our very own Anca Copaescu). You will learn about - Importance of category management - Key criteria for vendor onboarding - Vendor evaluation workflows - Risk Management - Latest trends and innovation

Get an inside look at how Prime Therapeutics is reshaping the PBM landscape!

Exciting insights from the 19th Annual HD Therapeutics Conference! Here's a brief recap of day one of the conference.  Stay tuned for more updates!  #HDResearch #HuntingtonsDisease #HDafrica

Welcome back to 2024! This year is gearing up to be even bigger than 2023 for Argenica Therapeutics, with Phase 2 clinical trial in acute ischaemic stroke (AIS) patients right around the corner. If you missed it, last month we provided a company update that addressed the current status of the clinical trial. ⬇ You can find the announcement here ⬇ AGN investor announcement: https://bit.ly/3NVPdWu #ASX #AGN #investor #clinicaltrial #clinicaltrialupdate #stroke #strokeawareness

Wrapping up the 19th Annual HD Therapeutics Conference 2024 with enlightening insights! Here's a brief recap from the final day of the conference. Stay tuned for more updates! #HDResearch #HuntingtonsDisease #ScientificAdvancements #HDAfrica

Qatar Investment Authority (QIA) dedicated to healthtech by investing in innovative healthcare companies as well as funds Latest investment in startups: 🇺🇸 Outpace Bio (Aug 2024, Series B, $144 million, CEO Marc Lajoie) is a cell therapy company using unrivaled AI-powered protein design to program immune cells for improved function inside patients battling solid tumors 🇺🇸 Iambic Therapeutics (Jun 2024, Series B+, $50 million, CEO Thomas Miller) is a clinical-stage biotechnology company developing novel therapeutics using its unique AI-driven discovery platform 🇬🇧 Autolus Therapeutics (Feb 2024, equity investment, $250 million + $350 million, CEO Christian Itin) is a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies 🇮🇳 Global Dental Services (Nov 2023, equity investment, $50 million, CEO Amarinder Singh) India's largest tech-enabled-dental-platform that operates more than 400 company-owned and company-operated dental clinics under the “Clove Dental" banner 🇺🇸 BridgeBio (Sep 2023, PIPE financing, $250 million, CEO Neil Kumar) is a commercial-stage biopharmaceutical company founded to discover, create, test, and deliver transformative medicines to treat patients who suffer from genetic diseases and cancers with clear genetic drivers 🇺🇸 Star Therapeutics (Sep 2023, Series C, $90 million, CEO Adam Rosenthal) is a biotechnology company with a mission to develop life-changing therapies for as many rare diseases as possible for the millions of patients in urgent need Contact QIA Healthcare Investment Team https://lnkd.in/ezbyKmtM Investment in funds: 🇶🇦🤝🇫🇷 Future French Champions (May 2024, €300 million) is a joint-venture between Qatar Investment Authority (QIA) and Bpifrance that has invested almost €600 million over two phases to boost economic growth and innovation in France. As the 3rd phase, they have announced intention to increase their commitment by up to another €300 million once the current commitment is fully deployed.  The strategic priorities:  🤖 Artificial Intelligence (AI) 🏿 Semiconductors ⚛️ Quantum Computing 🏥 Healthcare 🚀 Aerospace ⚡ Energy Transition This year, QIA also announced (https://lnkd.in/eARVkTBT) the creation of a $1 billion VC fund of funds to support the development of the local entrepreneurial ecosystem. The sectors of interest: 🖥 Technology 🏥 Healthcare 💳 Fintech 🎓 Edtech Contact QIA Funds Investment Team https://lnkd.in/eRVD5r7k 

Do you want an update on what's been happening at Argenica Therapeutics? This morning, we released our most recent Investor Presentation, providing an update on our Phase 2 Clinical Trial. Read the full presentation here➡️ https://bit.ly/4f4NZ70 #clinicaltrial #investorupdate #AGN #ASX #stroke #strokeawareness

As an early investor in Dyne Therapeutics, CureDuchenne is pleased to share that Dyne announced positive data from their Phase 1/2 trial of DYNE-251 in individuals with #Duchenne amenable to skipping exon 51. Individuals treated with 20 mg/kg once every 4 weeks for 6 months showed a mean dystrophin expression of 3.7% of normal when unadjusted for muscle content; when adjusted for muscle contest, the mean was 8.72% of normal dystrophin. Improvements were observed in multiple functional endpoints in the 20 mg/kg cohort at 6 months, as well as the 10 mg/kg group which was escalated to 20 mg/kg during the open-label extension (6 months to 1 year). Dyne is initiating registrational cohorts and will update us later this year with their plans for pursuing FDA approval via the accelerated pathway. #exonskipping #CureDuchenne #DMD #FDA #ClinicalTrials https://lnkd.in/g94sfmix